Evaluation of Safety and Efficacy of DM-28 for Treatment of Moderate to Severe Ocular Dryness

Horus Pharma

Status

Completed

Conditions

Dry Eye

Treatments

Device: DM-28

Study type

Interventional

Funder types

Industry

Identifiers

NCT06607237

23E2474

Details and patient eligibility

About

This study is a pilot, exploratory study to check safety and efficacy of DM-28 device, a new medical device intended to treat moderate to severe ocular dryness.

Enrollment

44 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subject with a moderate to severe dry eye syndrome.
Subject with a score ≥ 23 for the OSDI (Ocular Surface Disease Index).
Subject with at least one eye with:
- Global ocular staining (cornea and conjunctiva) ≥4 and ≤9 on the Oxford scale (0 to 15)

AND one of the following criteria:

Schirmer test ≥ 3 mm/5 min and ≤ 9 mm/5 min OR
Sum of 3 measurements of Tear film Break-Up Time (TBUT) ≤ 30s.
- Subject, having given freely and expressly his/her informed consent.
- Subject who is able to comply with the study requirements, as defined in the present CIP, at the Investigator's appreciation (investigator expertise).
- Subject being affiliated to a health social security system.
- Female subjects of childbearing potential should use a medically accepted contraceptive regimen since at least 12 weeks before the beginning of the study, during all the study and at least 1 month after the study end (subject declaration).

Exclusion criteria

Far best corrected visual acuity (FBCVA) < 1/10 (according to Snellen Chart)
Subject with severe ocular dryness with one of these conditions (investigator expertise):
- Eyelid or blinking malfunction
- Corneal disorders not related to dry eye syndrome
- Ocular metaplasia
- Filamentous keratitis
- Corneal neovascularization
Subject with severe meibomian gland dysfunction (MGD)
History of ocular trauma, infection or inflammation, not related to dry eye syndrome within the last 3 months prior to the inclusion
History of ocular allergy or ocular herpes within the last 12 months.
Any troubles of the ocular surface not related to dry eye syndrome.
Subject with hypersensitivity to one of the components of the investigational device.
Subjects who underwent ocular surgery, including laser surgery, in either eye within the last 6 months.
Use of the following systemic or ocular treatments: isotretinoïd, cyclosporine, tacrolimus, sirolimus, pimecrolimus, punctual plugs, corticoids or dry eye therapy (intense pulse light, stem cells) during the month preceding the inclusion.
Subjects who have received ocular therapy (either eye) with any ophthalmic medication, except tear substitutes, within 2 weeks prior to study start or expected to receive ocular therapy during the study.
Any not stabilized systemic treatment, which can have an effect on performance or safety criteria, at the investigator appreciation.
Pregnant or nursing woman or planning a pregnancy during the study (subject declaration/ pregnancy test).
Subject deprived of freedom by administrative or legal decision (subject declaration).
Subject in a social or health institution (subject declaration).
Subject who is under guardianship or who is not able to express his/her consent (subject declaration/ investigator expertise).
Subject being in an exclusion period for a previous study (subject declaration).
Subject suspected to be non-compliant according to the Investigator's judgment (investigator expertise).
Subject wearing contact lenses during the study